BioID2 Proximity Labeling Services for Low-Toxicity Interactome Mapping

Choose BioID2 when: (1) your bait protein is small (TurboID is the better choice.

BioID2 (26 kDa) is 9 kDa smaller than BioID and TurboID (35 kDa each), and 2 kDa smaller than miniTurbo (28 kDa). For reference, GFP is ~27 kDa — BioID2 is comparable in size to a fluorescent protein tag. This size reduction matters most when the bait protein is under ~50 kDa — where a 35 kDa fusion nearly doubles the effective molecular weight and can sterically block interaction interfaces, disrupt folding, or mislocalize the fusion protein. Kim et al. (2016) demonstrated that BioID2's smaller size directly improved targeting fidelity at the nuclear envelope compared to original BioID.

Two reasons: (1) BioID2 is derived from Aquifex aeolicus BirA, not E. coli BirA — the bacterial enzyme from a thermophilic organism shows less promiscuous activity at 37°C, producing cleaner labeling with fewer non-specific biotinylation events. (2) BioID2 requires only a single point mutation (R40G) to achieve promiscuity, whereas original BioID required multiple mutations — each additional mutation increases the risk of off-target activity. The combination of a cleaner starting enzyme and fewer engineering changes results in BioID2's improved signal-to-noise ratio.

Yes — and BioID2's low toxicity makes it particularly well-suited for in vivo applications. Biotin is administered via drinking water (mice) or culture medium (worms, flies, plants) at standard concentrations; BioID2 labels over 16–18 hours without the elevated metabolic burden of TurboID's 500 µM biotin requirement. BioID2 has been validated in C. elegans, Drosophila, and Arabidopsis. For tissue-specific expression, AAV or lentiviral delivery of BioID2 fusions is compatible with standard transduction protocols — BioID2's smaller coding sequence (~700 bp) is advantageous for AAV packaging limits.

Three controls are recommended: (1) BioID2-only (no bait fusion) — expressed at comparable levels to subtract non-specific biotinylation, (2) no-biotin control — identifies endogenous biotinylated proteins and streptavidin-binding contaminants, and (3) a catalytically dead BioID2 variant (R40G revertant) fused to the bait — controls for expression-level effects, though this is optional for well-characterized baits. Biological triplicates are essential for SAINTexpress statistical scoring. For subcellular-targeted BioID2, a mislocalized control (e.g., cytosolic BioID2 for a nuclear-targeted experiment) provides spatial specificity validation.

AP-MS enriches bait complexes from cell lysates under native conditions — this works for stable complexes but loses weak/transient interactions (dissociation during lysis) and membrane protein complexes (detergent artifacts). BioID2 applies the biotin tag covalently before lysis — weak interactors are captured in situ, membrane proteins are solubilized by denaturing lysis without disrupting pre-existing interactions, and stringent washes eliminate post-lysis background. The trade-off: BioID2 labels all proteins within ~10 nm — including bystanders in the same compartment — requiring SAINT/CRAPome filtering. For stable, high-affinity complexes, AP-MS may provide more direct complex member identification; for the broader interaction neighborhood including weak and membrane-proximal partners, BioID2 is the appropriate choice.